Bruker (BRKR) Stock Price, News & Analysis

Company Overview

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research. Bruker also provides consumables, software, technical support and other services associated with its instruments.

Bruker was founded in 1960 by Günther Laukien and is headquartered in Billerica, Massachusetts. The company serves customers across North America, Europe, Asia and other international markets. Frank H. Laukien, a member of the founding family, serves as Bruker’s president and chief executive officer.

Key Stats

• Today's Range: $59.30 to $66.42
• 50-Day Range: $50.30 to $64.75
• 52-Week Range: $32.37 to $66.98
• Volume: 597,293 shs
• Average Volume: 2.35 million shs
• Market Capitalization: $9.13 billion
• P/E Ratio: N/A
• Dividend Yield: 0.33%
• Price Target: $57.86
• Consensus Rating: Moderate Buy

Bruker Stock Analysis - MarketRank™

Bruker scored higher than 46% of companies evaluated by MarketBeat, and ranked 554th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bruker has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 2 strong buy ratings, 6 buy ratings, 5 hold ratings, and 1 sell rating.

Downside Risk

Bruker has a consensus price target of $57.86, representing about 10.4% downside from its current price of $64.60.

Amount of Analyst Coverage

Bruker has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 14.62%

Earnings Growth

Earnings for Bruker are expected to grow by 14.62% in the coming year, from $2.12 to $2.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bruker is -93.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bruker is -93.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bruker has a PEG Ratio of 1.93. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bruker has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.26% of the float of Bruker has been sold short.

Short Interest Ratio / Days to Cover

Bruker has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Bruker has recently increased by 4.04%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Bruker has a dividend yield of 0.32%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bruker does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Bruker will have a dividend payout ratio of 8.23% next year. This indicates that Bruker will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.61

News Sentiment

Bruker has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Bruker this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for BRKR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Bruker to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bruker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,740.00 in company stock.

Percentage Held by Insiders

27.20% of the stock of Bruker is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.52% of the stock of Bruker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Record date for 10/7 Dividend: 9/21/2026
• Ex-Dividend for 10/7 Dividend: 9/21/2026
• Today: 10/06/2026
• Dividend Payable: 10/07/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:BRKR
• CIK: 1109354
• Web: www.bruker.com
• Phone: (978) 663-3660
• Fax: 978-663-5585
• Employees: 11,085
• Year Founded: 1960

Price Target and Rating

• Average Price Target for Bruker: $57.86
• High Price Target: $80.00
• Low Price Target: $35.00
• Potential Upside/Downside: -3.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 28.18
• P/E Growth: 1.93
• Net Income: -$8.60 million
• Net Margins: -2.35%
• Pretax Margin: -0.64%
• Return on Equity: 12.47%
• Return on Assets: 4.91%

Debt

• Debt-to-Equity Ratio: 0.76
• Current Ratio: 1.85
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: $3.44 billion
• Price / Sales: 2.65
• Cash Flow: $3.19 per share
• Price / Cash Flow: 18.73
• Book Value: $16.28 per share
• Price / Book: 3.67

Miscellaneous

• Outstanding Shares: 152,360,000
• Free Float: 110,917,000
• Market Cap: $9.10 billion
• Optionable: Optionable
• Beta: 1.22